A Phase 3 interventional study of Placebo and Hydrocodone bitartrate in Back Pain Lower Back Chronic, sponsored by Zogenix, Inc.. Completed at 51 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-08.
Sponsored by Zogenix, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,283 studies in Chronic Pain with a site in United States — 257 open to participants now, 348 under way, 7 of them phase 3. Chronic Pain · United States.
Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 57th largest by enrollment of the 1,092 interventional ones that give a count, is one of 26 that started in 2010, is one of 65 in phase 3, and was the 110th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →257 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:
University of Oklahoma · Sites in United States
Ages 18–120
Virginia Polytechnic Institute and State University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18+ · Women only
University of Massachusetts, Boston · Sites in United States
Ages 65+
Stanford University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 81 · Phase 2 112 · Phase 3 72 · Phase 4 50
First in 1992; this study’s year is marked. 26 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 510 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 60 across the 1,092 interventional studies, 100 across the 189 observational. Of the 848 that completed or were terminated, 386 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
209 of 1,283 have an industry lead sponsor. The 10 most frequent:
This study is registered under Zogenix, Inc., one of the names counted as UCB S.A.. Under that name alone:
Zogenix, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
UCB S.A. has 3 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
139 of the studies in Chronic Pain with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05703178Phase 3Northwestern UniversityWeb-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia | 2026-11-30 |
| NCT06091202Phase 3Oregon Health and Science UniversityTele-Collaborative Outreach to Rural Patients With Chronic Pain | 2027-05-01 |
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT03984565Staci Gruber, Ph.D.PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product | 2026-11 |
Add all 139 to your calendar (.ics) → With an account.
Among the 1,283 studies in Chronic Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety and efficacy of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain.
A randomized Phase 3, placebo-controlled multi-center study to evaluate the safety, efficacy and tolerability of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain. Subjects will go through an open-label conversion and titration phase followed by a randomized double-blind treatment phase of Hydrocodone (HC)-Controlled-Release (CR) vs. Placebo. The trial will consist of a Screening Phase (up to 14 days), an open-label Conversion and Titration Phase (up to 6 weeks), a 12-week placebo-controlled Treatment Phase, and a 2-week Follow-Up Phone Call
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hydrocodone Bitartrate Controlled-Release Capsules
Drug: Hydrocodone bitartrate
Drug: Placebo
Capsules, no active substance, shells identical to active comparator capsules
Also known as: Sugar pill
dosage form: capsule Strengths 10mg, 20mg, 30mg, 40mg, 50mg
Mean Change in 24-hour Pain Intensity Ratings Scale (NRS).
Change in average pain intensity as measured daily by Numeric Rating Scale (NRS) for Pain (0-10; where 0 = no pain, 10 = worst pain imaginable) comparing HC-ER with Placebo. Lower number equals better outcome.
Time frame: Baseline to Day 85 (Treatment Phase)
Mean Change of the Clinic NRS Pain Intensity
The change in pain intensity as measured in the clinic by a 0-10 Numeric Rating Scale (NRS)
Time frame: Baseline to Day 85 visit
| Milestone | Conversion/Titration Phase - Open-Label | Double-Blind Treatment Phase | Double-Blind Treatment Phase: Placebo Comparator |
|---|---|---|---|
| Started | 510 | 0 | 0 |
| Completed | 302 | 0 | 0 |
| Not completed | 208 | 0 | 0 |
| Withdrew: Adverse event | 47 | 0 | 0 |
| Withdrew: Lack of efficacy | 17 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 |
| Withdrew: Protocol violation | 67 | 0 | 0 |
| Withdrew: Withdrawal by subject | 23 | 0 | 0 |
| Withdrew: Non-compliance | 47 | 0 | 0 |
| Milestone | Conversion/Titration Phase - Open-Label | Double-Blind Treatment Phase | Double-Blind Treatment Phase: Placebo Comparator |
|---|---|---|---|
| Started | 0 | 151 | 151 |
| Completed | 0 | 124 | 59 |
| Not completed | 0 | 27 | 92 |
| Withdrew: Adverse event | 0 | 2 | 12 |
| Withdrew: Lack of efficacy | 0 | 14 | 64 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 5 | 5 |
| Withdrew: Non-compliance | 0 | 4 | 7 |
| Withdrew: Withdrawal by medical monitor | 0 | 0 | 1 |
Change in average pain intensity as measured daily by Numeric Rating Scale (NRS) for Pain (0-10; where 0 = no pain, 10 = worst pain imaginable) comparing HC-ER with Placebo. Lower number equals better outcome.
| units on a scale | Hydrocodone Bitartrate Capsules | Placebo Comparator |
|---|---|---|
| Mean Change in 24-hour Pain Intensity Ratings Scale (NRS). | 0.48 ± 1.563 | 0.96 ± 1.550 |
The change in pain intensity as measured in the clinic by a 0-10 Numeric Rating Scale (NRS)
Results for this outcome have not been posted.
Collected over Adverse events (AEs) were recorded up to 19 weeks, beginning at the Conversion and Titration Phase through 14 days after the last treatment administration (Treatment Phase).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-Label Conversion/Titration Phase | — | 6/510 (1.2%) | 253/510 (49.6%) |
| Double Blind Treatment Phase: Hydrocodone Bitartrate Capsules | — | 10/151 (6.6%) | 60/151 (39.7%) |
| Double Blind Treatment Phase: Placebo Comparator | — | 0/151 (0%) | 46/151 (30.5%) |
| Event | Open-Label Conversion/Titration Phase | Double Blind Treatment Phase: Hydrocodone Bitartrate Capsules | Double Blind Treatment Phase: Placebo Comparator |
|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 1/510 | 1/151 | 0/151 |
| AnaemiaBlood and lymphatic system disorders | 0/510 | 1/151 | 0/151 |
| Abdominal distensionGastrointestinal disorders | 0/510 | 1/151 | 0/151 |
| DiarrhoeaGastrointestinal disorders | 0/510 | 1/151 | 0/151 |
| NauseaGastrointestinal disorders | 0/510 | 1/151 | 0/151 |
| Ovarian abscessInfections and infestations | 0/510 | 1/151 | 0/151 |
| HypokalemiaMetabolism and nutrition disorders | 0/510 | 1/151 | 0/151 |
| Intervertebral disc disorderMusculoskeletal and connective tissue disorders | 0/510 | 1/151 | 0/151 |
| DepressionPsychiatric disorders | 0/510 | 1/151 | 0/151 |
| Homicidal ideationPsychiatric disorders | 0/510 | 1/151 | 0/151 |
| Event | Open-Label Conversion/Titration Phase | Double Blind Treatment Phase: Hydrocodone Bitartrate Capsules | Double Blind Treatment Phase: Placebo Comparator |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 56/510 | 12/151 | 0/151 |
| NauseaGastrointestinal disorders | 50/510 | 11/151 | 5/151 |
| Withdrawal syndromePsychiatric disorders | 3/510 | 1/151 | 9/151 |
| Urinary Tract InfectionInfections and infestations | 4/510 | 8/151 | 3/151 |
| DiarrhoeaGastrointestinal disorders | 11/510 | 4/151 | 8/151 |
| SomnolenceNervous system disorders | 24/510 | 1/151 | 0/151 |
| VomitingGastrointestinal disorders | 14/510 | 7/151 | 1/151 |
| InsomniaPsychiatric disorders | 12/510 | 3/151 | 7/151 |
| FatigueGeneral disorders | 21/510 | 1/151 | 2/151 |
| Back PainMusculoskeletal and connective tissue disorders | 4/510 | 6/151 | 5/151 |
Out of 510 subjects treated with Hydrocodone Bitartrate Extended Release (HC-ER) capsules in the Conversion/Titration Phase, 208 subjects discontinued early and 151 subjects were randomized into each of the two treatment groups (Maintenance HC-ER Treatment and Placebo Treatment).
| Age, Categorical(Participants) | Open-label Conversion/Titration Phase |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 462 |
| >=65 years | 48 |
| Sex: Female, Male(Participants) | Open-label Conversion/Titration Phase |
|---|---|
| Female | 273 |
| Male | 237 |
| Region of Enrollment(participants) | Open-label Conversion/Titration Phase |
|---|---|
| United States | 510 |
The record gives a start of Mar 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 2 years 6 months after primary completion. A results delay was requested in Jul 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hydrocodone